LITHIUM SALTS IN EXPERIMENTAL ONCOLOGY (REVIEW)

Recently, lithium salts have been considered as potential compounds for targeted therapy that can reduce tumor growth. There are a large number of publications indicating the effects of lithium on the signaling pathways used by tumor cells for growth and development, and have demonstrated that lithium can be used as antitumor agent in experimental oncology. The promise of using lithium salts to develop anticancer drugs is related to the fact that lithium has 2 main intracellular targets: glycogen synthase kinase-3β (GSK-3β) and inositol monophosphatase (IMPase), the inhibition of which by lithium can induce cancer cell death by apoptosis or autophagy. Lithium has been shown to block the proliferation of cancer cells by cell cycle arrest in the G₂ /M phase, and also stimulates apoptosis and autophagy in cancer cells. This review summarizes data on the transport of lithium across cell membranes, characterizes its main intracellular targets and presents the results of studies in which lithium was used

1. Bgatova N.P., Gavrilova Yu.S., Lykov A.P., Solovieva A.O., Makarova V.V., Borodin Yu.I., Konenkov V.I. Аpoptosis and autophagy in hepatocarcinoma cells induced by different forms of lithium salts. Cell Tissue Biol. 2017. 11 (4): 261–267. doi 10.1134/S1990519X17040022

2. Taskaeva Yu.S, Bgatova N.P. Ultrastructural changes in hepatocellular carcinoma-29 cells after treatment with lithium carbonate. Bull. Exp. Biol. Med. 2019. 167. (1): 87–90. doi 10.1007/s10517-019-04467-3

3. Altamura A.C., Gomeni R., Sacchetti E., Smeraldi E. Plasma and intracellular kinetics of lithium after oral administration of various lithium salts. Eur. J. Clin. Pharmacol. 1977; 12 (1): 59–63.

4. Berridge M.J., Downes C.P., Hanley M.R. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem. J. 1982; 206 (3): 587–595.

doi 10.1042/bj2060587

5. Beurel E., Blivet-Van Eggelpoël M.J., Kornprobst M., Moritz S., Delelo R., Paye F., Housset C., Desbois-Mouthon C. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells. Biochem. Pharmacol. 2009; 77 (1): 54–65. doi 10.1016/j.bcp.2008.09.026

6. Bijur G.N., Jope R.S. Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport. 2003; 14 (18): 2415–2419. doi 10.1097/00001756-200312190-00025

7. Can A., Schulze T.G., Gould T.D. Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol. Biochem. Behav. 2014; 123. 3–16. doi 10.1016/j.pbb.2014.02.004

8. Cockle J.V., Picton S., Levesley J., Ilett E., Carcaboso A.M., Short S., Steel LP., Melcher A., Lawler S.E., Brüning-Richardson A. Cell migration in paediatric glioma; characterisation and potential therapeutic targeting. Br. J. Cancer. 2015; 112 (4): 693–703. doi 10.1038/bjc.2015.16

9. Cohen Y., Chetrit A., Cohen Y., Sirota P., Modan B. Сancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med. Oncol. 1998. 1. 32–36.

10. Costabile V., Duraturo F., Delrio P., Rega D., Pace U., Liccardo R., Rossi G.B., Genesio R., Nitsch L., Izzo P., De Rosa M. Lithium chloride induces mesenchymal‑to‑epithelial reverting transition in primary colon cancer cell cultures. Int. J. Oncol. 2015; 46 (5): 1913–1923. doi 10.3892/ijo.2015.2911

11. de Araujo W.M., Robbs B.K., Bastos L.G., de Souza W.F., Vidal F.C., Viola J.P., Morgado-Diaz J.A. PTEN overexpression cooperates with lithium to reduce the malignancy and to increase cell death by apoptosis via PI3K/AKT suppression in colorectal cancer cells. J. Cell Biochem. 2016; 117 (2): 458–469. doi 10.1002/jcb.25294

12. Erdal E., Ozturk N., Cagatay T., Eksioglu-Demiralp E., Ozturk M. Lithium-mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells. Int. J. Cancer.  2005; 115 (6): 903–910. doi 10.1002/ijc.20972

13. Freland L., Beaulieu J.M. Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front. Mol. Neurosci. 2012; 5: 14. doi 10.3389/fnmol.2012.00014

14. Fu Y., Jiao Y., Zheng S., Liang A., Hu F. Combination of lithium chloride and pEGFP-N1-BmK CT effectively decreases proliferation and migration of C6 glioma cells. Cytotechnology. 2016; 68 (2): 197–202. doi 10.1007/s10616-014-9768-2

15. Furuta T., Sabit H., Dong Y., Miyashita K., Kinoshita M., Uchiyama N., Hayashi Y., Hayashi Y., Minamoto T., Nakada M. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Oncotarget. 2017; 8 (14): 22811–22824. doi 10.18632/oncotarget.15206

16. Gao S., Li S., Duan X., Gu Z., Ma Z., Yuan X., Feng X., Wang H. Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity. Mol. Carcinog. 2017; 56 (10): 2301–2316. doi 10.1002/mc.22685

17. Hallcher L.M., Sherman W.R. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 1980; 255 (22): 10896–10901.

18. Han S., Meng L., Jiang Y., Cheng W., Tie X., Xia J., Wu A. Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling. Br. J. Cancer. 2017; 116 (10): 1302–1311. doi 10.1038/bjc.2017.89

19. Huang R.Y., Hsieh K.P., Huang W.W., Yang Y.H. Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study. Br. J. Psychiatry. 2016; 209 (5): 393–399. doi 10.1192/bjp.bp.116.181362

20. Jakobsson E., Argüello-Miranda O., Chiu S.W., Fazal Z., Kruczek J., Nunez-Corrales S., Pandit S., Pritchet L. Towards a unified understanding of lithium action in basic biology and its significance for applied biology. J. Membr. Biol. 2017; 250 (6): 587–604. doi 10.1007/s00232-017-9998-2

21. Li H., Huang K., Liu X., Liu J., Lu X., Tao K., Wang G., Wang J. Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3β/NF-κB signaling pathway. Oxid. Med. Cell Longev. 2014; 2014: 241864. doi 10.1155/2014/241864

22. Li L., Song H., Zhong L., Yang R., Yang X.Q., Jiang K.L., Liu B.Z. Lithium chloride promotes apoptosis in human leukemia NB4 cells by inhibiting glycogen synthase kinase-3 beta. Int. J. Med. Sci. 2015; 12 (10): 805–810. doi 10.7150/ijms.12429

23. Maeng Y.S., Lee R., Lee B., Choi S.I., Kim E.K. Lithium inhibits tumor lymphangiogenesis and metastasis through the inhibition of TGFBIp expression in cancer cells. Sci. Rep. 2016; 6: 20739. doi 10.1038/srep20739

24. Malhi G.S., Tanious M., Das P., Berk M. The science and practice of lithium therapy. Aust. N. Z. J. Psychiatry. 2012; 46 (3): 192–211. doi 10.1177/0004867412437346

25. Mancinelli R., Carpino G., Petrungaro S., Mammola C.L., Tomaipitinca L., Filippini A., Facchiano A., Ziparo E., Giampietri C. Multifaceted roles of GSK-3 in cancer and autophagy-related diseases. Oxid. Med. Cell Longev. 2017; 2017: 4629495. doi 10.1155/2017/4629495

26. Martinsson L., Westman J., Hällgren J., Ösby U., Backlund L. Lithium treatment and cancer incidence in bipolar disorder. Bipolar Disord. 2016; 18 (1): 33–40. doi 10.1111/bdi.12361

27. McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Sokolosky M., Abrams S.L., Montalto G., D'Assoro A.B., Libra M., Nicoletti F., Maestro R., Basecke J., Rakus D., Gizak A., Demidenko Z.N., Cocco L., Martelli A.M., Cervello M. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 2014; 5 (10): 2881–2911. doi 10.18632/oncotarget.2037

28. Mota de Freitas D., Leverson B.D., Goossens J.L. Lithium in medicine: mechanisms of action. Met. Ions Life Sci. 2016; 16: 557–584. doi 10.1007/978-3-319-21756-7_15

29. O'Donovan T.R., Rajendran S., O'Reilly S., O'Sullivan G.C., McKenna S.L. Lithium modulates autophagy in esophageal and colorectal cancer cells and enhances the efficacy of therapeutic agents in vitro and in vivo. PLoS One. 2015; 10 (8): e0134676. doi 10.1371/journal.pone.0134676

30. Oruch R., Elderbi M.A., Khattab H.A., Pryme I.F., Lund A. Lithium: a review of pharmacology, clinical uses, and toxicity. Eur. J. Pharmacol. 2014; 740: 464–473. doi 10.1016/j.ejphar.2014.06.042

31. Pasquali L., Busceti C.L., Fulceri F., Paparelli A., Fornai F. Intracellular pathways underlying the effects of lithium. Behav. Pharmacol. 2010; 21 (5–6): 473–492. doi 10.1097/FBP.0b013e32833da5da

32. Peixoto-da-Silva J., Calgarotto A.K., Rocha K.R., Palmeira-Dos-Santos C., Smaili S.S., Pereira G.J.S., Pericole F.V., da Silva S. Duarte A., Saad S.T.O., Bincoletto C. Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects. Biomed. Pharmacother. 2018; 99: 237–244. doi 10.1016/j.biopha.2018.01.027

33. Phiel C.J., Klein P.S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 789–813. doi 10.1146/annurev.pharmtox.41.1.789

34. Quiroz J.A., Gould T.D., Manji H.K. Molecular effects of lithium. Mol. Interv. 2004; 4 (5): 259–272. doi 10.1124/mi.4.5.6

35. Richman L.S., Dzierba A.L., Connolly K.A., Bryan P.M., Chandra S. Artificial lithium toxicity: a case report and review of the literature. J. Pharm. Pract. 2015; 28 (5): 479–481. doi 10.1177/0897190015587698

36. Roux M., Dosseto A. From direct to indirect lithium targets: a comprehensive review of omics data. Metallomics. 2017; 9 (10): 1326–1351. doi 10.1039/c7mt00203c

37. Sade Y., Toker L., Kara N.Z., Einat H., Rapoport S., Moechars D., Berry G.T., Bersudsky Y., Agam G. IP3 accumulation and/or inositol depletion: two downstream lithium's effects that may mediate its behavioral and cellular changes. Transl. Psychiatry. 2016; 6 (12): e968. doi 10.1038/tp.2016.217

38. Sarkar S., Floto R.A., Berger Z., Imarisio S., Cordenier A., Pasco M., Cook L.J., Rubinsztein D.C. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 2005; 170 (7): 1101–1111. doi 10.1083/jcb.200504035

39. Schleicher S.B., Zaborski J.J., Riester R., Zenkner N., Handgretinger R., Kluba T., Traub F., Boehme K.A. Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines. PLoS One. 2017; 12 (6): e0178857. doi 10.1371/journal.pone.0178857

40. Taskaeva Iu., Bgatova N. Ultrastructural and immunofluorescent analysis of lithium effects on autophagy in hepatocellular carcinoma cells. Asian Pac. J. Cancer. Biol. 2018; 3 (3): 83–87. doi 10.22034/APJCB.2018.3.3.83

41. Toker L., Agam G. Lithium, inositol and mitochondria. ACS Chem. Neurosci. 2014; 5 (6): 411–412. doi 10.1021/cn5001149

42. Trnski D., Sabol M., Gojević A., Martinić M., Ozretić P., Musani V., Ramić S., Levanat S. GSK3β and Gli3 play a role in activation of Hedgehog-Gli pathway in human colon cancer - Targeting GSK3β downregulates the signaling pathway and reduces cell proliferation. Biochim. Biophys. Acta. 2015; 1852 (12): 2574–2584. doi 10.1016/j.bbadis.2015.09.005

43. Tsui M.M., Tai W.C., Wong W.Y., Hsiao W.L. Selective G2/M arrest in a p53 (Val135)-transformed cell line induced by lithium is mediated through an intricate network of MAPK and β-catenin signaling pathways. Life Sci. 2012; 91 (9-10): 312–321. doi 10.1016/j.lfs.2012.07.027

44. Vicencio J.M., Ortiz C., Criollo A., Jones A.W., Kepp O., Galluzzi L., Joza N., Vitale I., Morselli E., Tailler M., Castedo M., Maiuri M.C., Molgó J., Szabadkai G., Lavandero S., Kroemer G. The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ. 2009; 16 (7): 1006–1017. doi 10.1038/cdd.2009.34

45. Vosahlikova M., Svoboda P. Lithium – therapeutic tool endowed with multiple beneficiary effects caused by multiple mechanisms. Acta Neurobiol. Exp. (Wars.): 2016; 76 (1): 1–19.

46. Wang X., Fang Z., Wang A., Luo C., Cheng X., Lu M. Lithium suppresses Hedgehog signaling via promoting ITCH E3 ligase activity and Gli1-SUFU interaction in PDA cells. Front. Pharmacol. 2017; 8: 820. doi 10.3389/fphar.2017.00820

47. Wang X., Luo C., Cheng X., Lu M. Lithium and an EPAC-specific inhibitor ESI-09 synergistically suppress pancreatic cancer cell proliferation and survival. Acta Biochim. Biophys. Sin. (Shanghai): 2017; 49 (7): 573–580. doi 10.1093/abbs/gmx045

48. Wang Y., Zhang Q., Wang B., Li P., Liu P. LiCl treatment induces programmed cell death of schwannoma cells through AKT- and MTOR-mediated necroptosis. Neurochem. Res. 2017; 42 (8): 2363–2371. doi 10.1007/s11064-017-2256-2

49. Zassadowski F., Pokorna K., Ferre N., Guidez F., Llopis L., Chourbagi O., Chopin M., Poupon J., Fenaux P., Ann Padua R., Pla M., Chomienne C., Cassinat B. Lithium chloride antileukemic activity in is GSK-3 and MEK/ERK dependent. Leukemia. 2015; 29 (12): 2277–2284. doi 10.1038/leu.2015.159

50. Zinke J., Schneider F.T., Harter P.N., Thom S., Ziegler N., Toftgård R., Plate K.H., Liebner S. β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma. Mol. Cancer. 2015; 14: 17. doi 10.1186/s12943-015-0294-4

Taskaeva Iu.S., e-mail: inabrite@yandex.ru